scholarly journals `Me-Too' Innovation in Pharmaceutical Markets

2009 ◽  
Vol 12 (1) ◽  
Author(s):  
Anupam B Jena ◽  
John E. Calfee ◽  
Edward C Mansley ◽  
Tomas J Philipson
Keyword(s):  
Health Care ◽  
Health Insurance ◽  
Health Care Costs ◽  
Switching Costs ◽  
Clinical Value ◽  
Patent Expiration ◽  
Pharmaceutical Markets ◽  
Competitive Pricing ◽  
Care Costs

Critics of me-too innovation often argue that follow-on drugs offer little incremental clinical value over existing pioneer products, while at the same time increasing health care costs. We examine whether consumers view follow-on and pioneer drugs as close substitutes or distinct clinical therapies. For five major classes of drugs, we find that large reductions in the price of pioneer molecules after patent expiration—which would typically lead to decreased consumption of strong substitutes—have no effect on the trend in demand for follow-on drugs. Our findings are likely unaffected by health insurance, competitive pricing of me-toos, marketing, and switching costs.

scholarly journals Total health insurance costs in children with a migraine diagnosis compared to a control group

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Viola Obermeier ◽  
Monika Murawski ◽  
Florian Heinen ◽  
Mirjam N. Landgraf ◽  
Andreas Straube ◽  
...  
Keyword(s):  
Health Care ◽  
Health Insurance ◽  
Health Care Costs ◽  
Control Group ◽  
Health Insurance Data ◽  
German Health ◽  
Excess Costs ◽  
Headache Diagnosis ◽  
Migraine Group ◽  
Care Costs

Abstract Background Health care costs of migraine constitute a major issue in health economics. Several publications analyzed health care costs for adult migraine patients, based on questionnaires or secondary (health insurance) data. Although migraine often starts already in primary school age, data on migraine related costs in children is scarce. In this paper we aimed to assess the migraine-related health care costs in 6 to 11 year old children in Germany. Methods Using claims data of a large German health insurer (BARMER), overall annual health care costs of 6 to 11 year old children with a diagnosis of migraine in 2017 (n = 2597) were compared to a control group of 6 to 11 year old children without a headache diagnosis between 2013 and 2017 (n = 306,926). The association of migraine and costs was modeled by generalized linear regression (Gamma regression) with adjustment for sex, age and comorbidities. Results Children with migraine caused considerably higher annual per capita health care costs than children without a headache diagnosis (migraine group: € 1018, control group: € 618). Excess costs directly related to migraine amounted to € 115. The remaining excess costs were related to comorbidities, which were more frequent in the migraine group. Mental and behavioural disorders constituted the most expensive comorbidity, accounting for € 105 of the € 400 annual excess costs in the migraine group. Conclusion 6 to 11 year old children with a migraine diagnosis cause significant direct and comorbidity related excess costs in the German health care system.

On-Site Clinics

2016 ◽  
pp. 213-232
Author(s):  
Robert Yehl ◽  
Mary Eleanor Wickersham ◽  
Virginia B. Sizemore
Keyword(s):  
Health Care ◽  
Health Insurance ◽  
Health Care Costs ◽  
Local Governments ◽  
Economic Recession ◽  
Employee Health ◽  
Fiscal Constraints ◽  
Health Clinics ◽  
Care Costs ◽  
The U.S

With the continued rising cost of health insurance and the fiscal constraints as a result of the 2007-09 economic recession requiring local governments in the U.S. to make cuts in employees, services, and benefits, it appears that on-site health clinics are one method of reducing, or at least, slowing health care costs. This chapter analyzes the use and benefits of such clinics for local government managers that is a new, but potentially effective method of both controlling costs and improving employee health.

scholarly journals Health Care Costs in Patients With Type 2 Diabetes in Flanders Based on A Combination of Clinical And Health Insurance Data

2014 ◽  
Vol 17 (7) ◽  
pp. A341 ◽  
Author(s):  
I. Odnoletkova ◽  
L. Annemans ◽  
A. Ceuppens ◽  
B. Aertgeerts ◽  
D. Ramaekers
Keyword(s):  
Type 2 Diabetes ◽  
Health Care ◽  
Health Insurance ◽  
Health Care Costs ◽  
Health Insurance Data ◽  
Insurance Data ◽  
Care Costs

Association of SHI coverage and level of healthcare utilization and costs in the Philippines: a 10-year pooled analysis

2019 ◽  
Vol 42 (4) ◽  
pp. e496-e505
Author(s):  
Nel Jason L Haw ◽  
Jhanna Uy ◽  
Beverly Lorraine Ho
Keyword(s):  
Health Care ◽  
Health Insurance ◽  
Health Care Utilization ◽  
Health Care Costs ◽  
Inpatient Care ◽  
The Philippines ◽  
Care Utilization ◽  
Health Coverage ◽  
Outpatient Services ◽  
Care Costs

Abstract Background The Philippine Health Insurance Corporation (PhilHealth), which manages the Philippine national health insurance program, is a critical actor in the country’s strategy for universal health coverage. Over the past decade, PhilHealth has passed significant coverage, benefits and payment reforms to contain costs and improve the affordability care for high-cost diseases, inpatient care and select outpatient services. Methods We studied the association of PhilHealth with health care utilization and health care costs using three rounds of the Philippine Demographic and Health Survey with data on individual outpatient and inpatient visits from 2008 to 2017. Results PhilHealth membership was associated with 42% greater odds of outpatient utilization and 47–100% greater odds inpatient utilization depending on survey year. Depending on facility type, use of PhilHealth to pay for care was associated with higher average health care costs of 244–865% for outpatient care and 135–206% for inpatient care. Conclusions PhilHealth has likely decreased barriers to health care utilization but may have inadvertently driven up health care costs in the country. Results align with past studies that suggest that reforms in the prior decade have done little to contain health care costs for Filipinos.

scholarly journals Comparing Health Care Financial Burden With an Alternative Measure of Unaffordability

2017 ◽  
Vol 54 ◽  
pp. 004695801773296
Author(s):  
Edward S. Kielb ◽  
Corwin N. Rhyan ◽  
James A. Lee
Keyword(s):  
Health Care ◽  
Health Insurance ◽  
Medical Care ◽  
Health Care Costs ◽  
Health Plan ◽  
Low Income ◽  
Access To Health Care ◽  
Financial Burden ◽  
Access To Health ◽  
Care Costs

Health insurance plans with high deductibles increase exposure to health care costs, raising concerns about how the growth in these plans may be impacting both the financial burden of health care expenditures on families and their access to health care. We find that foregoing medical care is common among low-income, privately insured families, occurring at a greater rate than those with higher incomes or Medicare coverage. To better understand the relationship between out-of-pocket (OOP) spending and access, we used the 2011-2014 Medical Expenditure Panel Survey (MEPS) data and a logistic model to analyze the likelihood of avoiding or delaying needed medical care based on health insurance design and other individual and family characteristics. We find that avoiding or delaying medical care is strongly correlated with coverage under a high-deductible health plan, and with depression, poor perceived health, or poverty. However, it is relatively independent of the percent of income spent on OOP costs, making the percent of income spent on OOP costs by itself a poor measure of health care unaffordability. Individuals who spend a small percentage of their income on health care costs may still be extremely burdened by their health plan when financial concerns prevent access to health care. This work emphasizes the importance of insurance design as a predictor of access and the need to expand the definition of financial barriers to care beyond expenditures, particularly for the low-income, privately insured population.

scholarly journals A prospective randomized trial examining health care utilization in individuals using multiple smartphone-enabled biosensors

2015 ◽  
Author(s):  
Cinnamon S. Bloss ◽  
Nathan E. Wineinger ◽  
Melissa Peters ◽  
Debra L. Boeldt ◽  
Lauren Ariniello ◽  
...  
Keyword(s):  
Health Care ◽  
Health Insurance ◽  
Health Care Costs ◽  
Health Management ◽  
Self Management ◽  
Care Utilization ◽  
Randomized Controlled ◽  
Digital Medicine ◽  
Study Participants ◽  
Care Costs

ABSTRACTBackgroundMobile health and digital medicine technologies are becoming increasingly used by individuals with common, chronic diseases to monitor their health. Numerous devices, sensors, and apps are available to patients and consumers – some of which have been shown to lead to improved health management and health outcomes. However, no randomized controlled trials have been conducted which examine health care costs, and most have failed to provide study participants with a truly comprehensive monitoring system.MethodsWe conducted a prospective randomized controlled trial of adults who had submitted a 2012 health insurance claim associated with hypertension, diabetes, and/or cardiac arrhythmia. The intervention involved receipt of one or more mobile devices that corresponded to their condition(s) and an iPhone with linked tracking applications for a period of 6 months; the control group received a standard disease management program. Moreover, intervention study participants received access to an online health management system which provided participants detailed device tracking information over the course of the study. This was a monitoring system designed by leveraging collaborations with device manufacturers, a connected health leader, health care provider, and employee wellness program – making it both unique and inclusive. We hypothesized that health resource utilization with respect to health insurance claims may be influenced by the monitoring intervention. We also examined health-self management.Results & ConclusionsThere was little evidence of differences in health care costs or utilization as a result of the intervention. Furthermore, we found evidence that the control and intervention groups were equivalent with respect to most health care utilization outcomes. This result suggests there are not large short-term increases or decreases in health care costs or utilization associated with monitoring chronic health conditions using mobile health or digital medicine technologies. Among secondary outcomes there was some evidence of improvement in health self-management which was characterized by a decrease in the propensity to view health status as due to chance factors in the intervention group.Disclosure of FundingThis research is funded in part by a NIH/NCATS flagship Clinical and Translational Science Award Grant (1UL1 TR001114), Qualcomm Foundation Scripps Health Digital Medicine Research Grant, and Scripps Health’s Division of Innovation and Human Capital and Division of Scripps Genomic Medicine. Support for the study is also provided by HealthComp Third Party Administrator, Sanofi, AliveCor, and Accenture.Trial Registration: clinicaltrials.gov Identifier NCT01975428

Sign in / Sign up

Export Citation Format

Share Document